专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

91. 发明授权

US10751296B2 Curcuphenol compounds for increasing MHC-I expression 有权
公开(公告)号：US10751296B2
公开(公告)日：2020-08-25
申请号：US15415291
申请日：2017-01-25
申请人： CAVA HEALTHCARE INC.
发明人： Wilfred Jefferies , Reinhard Gabathuler , Raymond Andersen , Lilian Nohara , David Williams
IPC分类号： A61K31/045 , A61K31/05 , A61K31/12 , A61K45/06 , A61N5/10
摘要： Provided are methods of using curcuphenol compounds to increase expression of major histocompatibility complex class I (MHC-I) antigen in cells, particularly on the surface of diseased cells such as cancer cells, and thereby increase the immunogenicity of the cells. Also provided are pharmaceutical compositions that comprise curcuphenol compounds and methods of use thereof, for instance, to treat various cancers, alone or in combination with other therapies.

92. 发明申请

US20200246311A1 NASAL DECONGESTANT COMPOSITIONS COMPRISING DEXPANTHENOL AND SODIUM HYALURONATE 审中-公开
公开(公告)号：US20200246311A1
公开(公告)日：2020-08-06
申请号：US16637777
申请日：2018-08-06
申请人： ELIXIR ILAC ARASTIRMA VE GELISTIRME A.S.
发明人： Firat YERLIKAYA , Dilara AYDIN , Erden BANOGLU , Fikret ILERI
IPC分类号： A61K31/4164 , A61K31/16 , A61K47/36 , A61K31/045 , A61K9/06 , A61K9/00 , A61P11/02
摘要： A nasal pharmaceutical composition comprising a decongestant compound selected from xylometazoline or a pharmaceutically acceptable salt of xylometazoline, oxymetazoline or a pharmaceutically acceptable salt of oxymetazoline, menthol; dexpanthenol and hyaluronic acid or a pharmaceutically acceptable salt of hyaluronic acid.

93. 发明授权

US10729720B2 Peroxide formulations and methods and applicators for using the same 有权
公开(公告)号：US10729720B2
公开(公告)日：2020-08-04
申请号：US15961236
申请日：2018-04-24
申请人： ACLARIS THERAPEUTICS, INC.
发明人： Stuart D. Shanler , Christopher Powala , Christopher Phillips , Brian Beger , Charles Rodney Greenaway Evans , Sian Tiong Lim , Marc Barry Brown , Michael A. Botta , Thomas Nagler
IPC分类号： A61K33/40 , A61K9/08 , A61K9/00 , A61K8/34 , A61Q19/00 , A61Q19/08 , A61K8/22 , A61K47/10 , A61K31/045 , A61P17/00 , A61M35/00
摘要： Embodiments are directed to a stable composition comprising stabilized hydrogen peroxide and 2-propanol and applicators configured to store, dispense, and apply such stable compositions. Such compositions may be used to treat skin conditions such as warts, condyloma accuminatum, molluscum contagiosum, acrochordons, seborrheic keratosis, or a combination thereof. Some embodiments also describe take home compositions, in office compositions, over-the-counter compositions, and kits for the use of such compositions.

94. 发明授权

US10729715B2 Bi-functional co-polymer use for ophthalmic and other topical and local applications 有权
公开(公告)号：US10729715B2
公开(公告)日：2020-08-04
申请号：US15889493
申请日：2018-02-06
申请人： Eyeon Particle Sciences LLC
发明人： Eugene Rex Cooper , David Maxwell Kleinman , Andrew Loxley , Mark A. Mitchnick
IPC分类号： A61K31/785 , A61K9/00 , A61K9/51 , A61K31/74 , A61K47/34 , A61K35/02 , A61K31/765 , A61K45/06 , G02C7/04 , A61K9/50 , A61K31/045 , A61K31/7036
摘要： The invention contemplates a copolymer which is a graft or block copolymer useful to change wettability and surface characteristics of biological surfaces. Methods for use of these formulations and coatings to change wettability and sterically stabilize, and lubricate biological surfaces in a subject, for example, in the treatment of dry eye syndrome, and to prevent adherence of unwanted proteins, for example in the treatment of contact lens intolerance, are provided.

95. 发明申请

US20200237697A1 PHARMACEUTICAL COMPOSITIONS COMPRISING POH DERIVATIVES AND METHODS OF USE 审中-公开
公开(公告)号：US20200237697A1
公开(公告)日：2020-07-30
申请号：US16606520
申请日：2018-04-18
申请人： NEONC TECHNOLOGIES, INC.
发明人： Thomas CHEN , Daniel LEVIN , Satish PUPALLI
IPC分类号： A61K31/20 , A61K47/55 , A61K45/06 , A61K9/00 , A61K31/045
摘要： The present invention provides for a method of treating a disease such as cancer, comprising the step of administering to a patient a therapeutically effective amount of a perillyl alcohol derivative such as a perillyl alcohol ester, or an isoperillyl alcohol derivative such as an isoperillyl alcohol ester. The derivative may be a perillyl alcohol or an isoperillyl alcohol conjugated with a therapeutic agent such as valproic acid. The route of administration may vary, including inhalation, intranasal, oral, transdermal, intravenous, subcutaneous or intramuscular injection.

96. 发明申请

US20200230055A1 LIPOSOMES FOR INHIBITING BIOFILM FORMATION 审中-公开
公开(公告)号：US20200230055A1
公开(公告)日：2020-07-23
申请号：US16488516
申请日：2018-03-01
申请人： COMBIOXIN SA
发明人： Samareh AZEREDO DA SILVEIRA LAJAUNIAS , Frédéric LAJAUNIAS
IPC分类号： A61K9/127 , A61K31/045 , A61K31/685 , A61K31/688 , A61L2/18
摘要： The present invention relates to a composition comprising, preferably consisting of, (i) a single empty liposome, wherein said single empty liposome is selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; or (b) an empty liposome consisting of sphingomyelin; or (ii) a mixture of empty liposomes; wherein said mixture of empty liposomes comprises, preferably consists of, at least one empty liposome selected from (a) an empty liposome comprising cholesterol, wherein the amount of cholesterol is at least 30% (weight per weight), wherein preferably said empty liposome comprising, further preferably consisting of, cholesterol and sphingomyelin; (b) an empty liposome consisting of sphingomyelin; and (c) an empty liposome comprising, preferably consisting of, phosphatidylcholine and sphingomyelin; and at least one empty liposome independently of each other selected from an empty liposome comprising, preferably consisting of, lipids or phospholipids selected from cholesterol, sphingomyelins, ceramides, phosphatidylcholines, phosphatidylethanolamines, phosphatidylserines, diacylglycerols, and phosphatidic acids containing one or two or more saturated or unsaturated fatty acids longer than 4 carbon atoms and up to 28 carbon atoms; for use in a method for preventing or reducing biofilm formation or for eradicating or reducing existing biofilm.

97. 发明授权

US10710951B2 Pharmaceutical composition containing verbenone derivative for treating or preventing neurodegenerative disease 有权
公开(公告)号：US10710951B2
公开(公告)日：2020-07-14
申请号：US15432522
申请日：2017-02-14
申请人： KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION
发明人： Won Ki Kim , Yongseok Choi , Sumi Song
IPC分类号： A61K31/4402 , A61K31/402 , A61K31/122 , C07C49/86 , A61K31/401 , A23L29/00 , A23L33/105 , A61K45/06 , A61K31/18 , A61K31/4406 , A61K31/4409 , A61K31/045 , A61K31/435 , A61K31/495 , A61K31/53 , C07C49/798 , C07C49/813 , C07C49/835 , C07D207/02 , C07D213/50
摘要： The present invention relates to a pharmaceutical composition or a functional health food comprising a verbenone derivative and pharmaceutically acceptable salts thereof as active ingredients for treating or preventing a neurodegenerative disease. More specifically, the verbenone derivative according to the present invention reduces neuronal cell death and oxidative stress, and is highly effective in preventing ischemic brain damage and inflammatory cell migration in rats, thereby providing the pharmaceutical composition or the functional health food which is useful in treating neurodegenerative diseases.

98. 发明授权

US10682372B2 Intracellular ATP enhancer 有权
公开(公告)号：US10682372B2
公开(公告)日：2020-06-16
申请号：US15754842
申请日：2016-08-24
申请人： StaGen Co., Ltd.
发明人： Takeshi Nishino , Naoyuki Kamatani
IPC分类号： A61K31/426 , A61K31/708 , A61K31/4439 , A61K31/405 , A61K9/20 , A61K31/415 , A61K45/06 , A61K31/522 , A61K31/045 , A61K31/519
摘要： A problem to be solved by the present invention is to provide a substance having an effect of increasing intracellular ATP and, particularly, a potent ATP enhancer far surpassing the increasing effect of inosine or febuxostat alone.A human or animal intracellular ATP enhancer comprising a combination of A) and B): A) a xanthine oxidase/xanthine dehydrogenase inhibitor or a pharmaceutically acceptable salt thereof; and B) any one or more compounds selected from inosine, inosinic acid, hypoxanthine, and pharmaceutically acceptable salts thereof.

99. 发明申请

US20200163904A1 ENHANCED PURITY AND METHODS OF USE OF ABLATIVE ALCOHOL 审中-公开
公开(公告)号：US20200163904A1
公开(公告)日：2020-05-28
申请号：US15933631
申请日：2018-03-23
申请人： DARREN RUBIN
发明人： DARREN RUBIN
IPC分类号： A61K31/045 , A61M25/10
摘要： A liquid injectable pharmaceutical drug product consisting of no less than 99 percent ethanol comprised of no less than 99 percent ethanol active pharmaceutical ingredient with a volume of at least 0.05 mL to be injected into a patient as a method of ablating/lysing cells.

100. 发明授权

US10660883B2 Inhalable nicotine formulations, and methods of making and using thereof 有权
公开(公告)号：US10660883B2
公开(公告)日：2020-05-26
申请号：US16214754
申请日：2018-12-10
申请人： PHILIP MORRIS PRODUCTS S.A.
发明人： Alex Stenzler , Noe Zamel , Arthur Slutsky , Steven Ellis , Steve Han
IPC分类号： A61K31/465 , A61K31/045 , A61K47/10 , A24B15/16 , A61K47/26 , A61K9/00 , A24B15/167
摘要： The present invention provides dry powder formulations comprising nicotine, methods of using the same, and methods for making the same. The dry powder formulations may further comprise excipients, therapeutic agents, and flavor components. The dry powder formulations may be manufactured by dry processes and wet processes.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式